PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10908576-6	2000	A role for p38 MAP kinase was further substantiated by the observation that SB203580 blocked translocation of the cell death activator, Bax, from the cytosol to the mitochondria after treatment with SNP.	SB 203580	76-84	BCL2 associated X, apoptosis regulator	Homo sapiens	136-139	
14625298-6	2004	SB203580, a specific inhibitor of p38 MAPK, partially suppressed CAPE-induced p53 activation, Bax expression, and apoptosis, consistent with a mechanism by which CAPE leads to Bax activation, known to be regulated by p38 and p53.	SB 203580	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	94-97	
14625298-6	2004	SB203580, a specific inhibitor of p38 MAPK, partially suppressed CAPE-induced p53 activation, Bax expression, and apoptosis, consistent with a mechanism by which CAPE leads to Bax activation, known to be regulated by p38 and p53.	SB 203580	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	176-179	
14637186-11	2003	The expression of p53, phospho-serine 15 of p53, and Bax, and inactivate form of CPP32 was suppressed by a pretreatment of a specific p38 MAPK inhibitor, SB203580.	SB 203580	154-162	BCL2 associated X, apoptosis regulator	Homo sapiens	53-56	
14522966-7	2003	On the other hand, treatment with SB203580, a p38 MAPK-specific inhibitor, or expression of a dominant negative form of p38 MAPK suppressed phytosphingosine-induced translocation of the proapoptotic protein, Bax, from the cytosol to mitochondria, cytochrome c release, and subsequent caspase-9 activation but did not affect caspase-8 activation, indicating that activation of p38 MAPK is involved in the mitochondrial activation-mediated cell death pathway.	SB 203580	34-42	BCL2 associated X, apoptosis regulator	Homo sapiens	208-211	
12805646-9	2003	SB203580, a p38 MAP kinase inhibitor, blocked translocation of Bax to mitochondria, whereas SB202474, a control peptide, had no effect on translocation.	SB 203580	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66	
12805646-10	2003	Inhibition of p38 MAP kinase by SB203580 blocked all downstream effects of Bax translocation, including cytochrome c release, caspase activation, and internucleosomal DNA fragmentation.	SB 203580	32-40	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78	
34025070-15	2021	Furthermore, SB203580 significantly reversed changes in the bronchoalveolar lavage fluid protein concentration, Evans blue accumulation, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cell numbers, apoptosis-related proteins (cle-caspase3, Bim and Bax) and endothelial microstructure.	SB 203580	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	280-283	
22644961-4	2012	Collectively, we for the first time demonstrate that SB203580 synergistically enhances the resveratrol-induced apoptosis by accelerating Bax-mediated intrinsic pathway and initiating extrinsic pathway, suggesting a possible alternative therapeutic strategy for human lung cancer.	SB 203580	53-61	BCL2 associated X, apoptosis regulator	Homo sapiens	137-140	
32251495-6	2020	When compared with PQ group, the cells in both SP600125+PQ group and SB203580+PQ group had significantly increased viability and level of anti-apoptotic protein Bcl-2; and had decreased apoptotic rates, decreased levels of caspase-3 and -9, and decreased level of pro-apoptotic protein Bax.	SB 203580	69-77	BCL2 associated X, apoptosis regulator	Homo sapiens	286-289	
22644961-2	2012	We found that pretreatment with SB203580 enhanced the resveratrol-induced apoptosis by accelerating the intrinsic apoptotic pathway including Bax activation, loss of mitochondrial membrane potential, and activation of both caspase-9 and -3.	SB 203580	32-40	BCL2 associated X, apoptosis regulator	Homo sapiens	142-145	
31295040-7	2020	For signaling mechanism, the western blotting results showed elevated p38 MAPK activation, and the reduced Bcl-2 and enhanced Bax upon hesperetin treatment were partly reversed by p38 MAPK inhibitor SB203580.	SB 203580	199-207	BCL2 associated X, apoptosis regulator	Homo sapiens	126-129	
31357761-9	2019	SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P< 0.05).	SB 203580	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	116-119	
26849940-7	2016	While, SP600125 (one JNK inhibitor) and SB203580 (one p38 inhibitor) markedly up-regulated Bcl-2 level, down-regulated the levels of Bax, cleaved caspase-3/9, and obviously boosted Cytochrome c release induced by dioscin.	SB 203580	40-48	BCL2 associated X, apoptosis regulator	Homo sapiens	133-136	
25958204-6	2015	SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria.	SB 203580	34-42	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142	
25270341-11	2014	Doxorubicin in combination with SB203580 significantly reduced cell viability (P<0.01) and increased cell death (P<0.01), which may be associated with the inactivation of the p38 MAPK signaling pathway, followed by the induced expression of the pro-apoptotic protein Bax and a concomitant decrease in Bcl-2 expression.	SB 203580	32-40	BCL2 associated X, apoptosis regulator	Homo sapiens	273-276	
24593988-8	2014	Moreover, co-treatment of MCF-7 cells with THC and p38 MAPK inhibitor, SB203580, effectively reversed the dissipation in mitochondrial membrane potential (Deltapsim), and blocked THC-mediated Bax up-regulation, Bcl-2 down-regulation, caspase-3 activation as well as p21 up-regulation, suggesting p38 MAPK might mediate THC-induced apoptosis and G2/M arrest.	SB 203580	71-79	BCL2 associated X, apoptosis regulator	Homo sapiens	192-195	
24035100-5	2013	SB203580, a selective p38MAPK inhibitor, blocked the apoptosis induced by alpha-calendic acid and beta-calendic acid by upregulating Bcl-2/Bax ratio and inhibition of the activation of Caspase-3 and Caspase-9.	SB 203580	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142	
21769948-7	2012	Both p38 specific inhibitor, SB 203580, or p38 knockdown by specific siRNA, blocked 2ME induction of Bax phosphorylation.	SB 203580	29-38	BCL2 associated X, apoptosis regulator	Homo sapiens	101-104	
20825716-8	2010	The models treated with SB203580 could gradually elevate the sensitivity of HepG2/CDDP to cisplatin, block the detention of cell cycle, up-regulate the expression of Bax and down-regulate the expressions of Bcl-2 and P-gp.	SB 203580	24-32	BCL2 associated X, apoptosis regulator	Homo sapiens	166-169	
22862178-7	2012	Inhibitors of JNK (SP600125) and p38 MAPK (SB203580) suppressed HEAMQ-induced apoptosis and G2/M phase arrest, attenuated the activation of Bax, and blocked down-regulation of Bcl-2, XIAP and survivin in HEAMQ-treated U937 cells.	SB 203580	43-51	BCL2 associated X, apoptosis regulator	Homo sapiens	140-143	
21424124-11	2011	Western blotting data revealed that SB203580 sensitises cancer cells to 5-FU due to an increase in Bax expression.	SB 203580	36-44	BCL2 associated X, apoptosis regulator	Homo sapiens	99-102	
19801665-6	2009	In addition, SPE B and G308S increased binding of serine-phosphorylated STAT1 to the Bax promoter and Bax expression, which was decreased by SB203580.	SB 203580	141-149	BCL2 associated X, apoptosis regulator	Homo sapiens	85-88	
19950206-11	2010	Furthermore, SB203580, p38 inhibitor, reduced the apoptotic effect of BBR, and blocks the generation of ROS and NO as well as activation of Bax.	SB 203580	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	140-143	
19801665-6	2009	In addition, SPE B and G308S increased binding of serine-phosphorylated STAT1 to the Bax promoter and Bax expression, which was decreased by SB203580.	SB 203580	141-149	BCL2 associated X, apoptosis regulator	Homo sapiens	102-105	
19699753-7	2009	Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells.	SB 203580	18-26	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59	
16616945-9	2006	Ciglitazone treatment increased Bax expression and caused a loss of mitochondrial membrane potential, and its effect was prevented by N-acetylcysteine, PD98059, and SB203580.	SB 203580	165-173	BCL2 associated X, apoptosis regulator	Homo sapiens	32-35	
18718914-5	2008	JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) pretreatment attenuated 15d-PGJ(2)-mediated apoptosis and suppressed the p21(Waf1) and Bax expressions without affecting p53 protein accumulation.	SB 203580	48-56	BCL2 associated X, apoptosis regulator	Homo sapiens	145-148	
18813787-5	2008	In this study, the activation of p38 was found to be critical for the p28GANK knockdown-induced apoptosis, as suggested by the finding that pharmacological inhibition of p38 with SB203580 suppressed the redistribution of Bax, the loss of DeltaPsim and the apoptosis.	SB 203580	179-187	BCL2 associated X, apoptosis regulator	Homo sapiens	221-224	
17237268-7	2007	Inhibition of p38 MAPK by treatment of SB203580 or expression of dominant-negative forms of p38 MAPK suppressed the combination treatment-induced Bax relocalization but did not affect PARP-1 activation.	SB 203580	39-47	BCL2 associated X, apoptosis regulator	Homo sapiens	146-149	
16730326-7	2006	Clustering of Bax into distinct regions on mitochondria could be prevented by CsA, an inhibitor of the mitochondrial permeability transition pore, and also by SB203580, an inhibitor of p38 MAPK.	SB 203580	159-167	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17	
16730326-8	2006	Surprisingly, mitochondrial fragmentation which occurred during ischemia and before Bax translocation could be reversed by the addition of the p38 inhibitor SB203580 at reperfusion.	SB 203580	157-165	BCL2 associated X, apoptosis regulator	Homo sapiens	84-87